賽諾菲宣布，達必(bi)妥(tuo)(度(du)普(pu)利尤單(dan)抗(kang)注(zhu)射液)獲得中(zhong)國國家藥品監(jian)督管理局(ju)(NMPA)批準，可(ke)(ke)用(yong)于(yu)(yu)6個(ge)月至(zhi)5歲患有中(zhong)重(zhong)(zhong)度(du)特應性皮(pi)炎(atopic dermatitis，AD)的(de)嬰(ying)幼兒(er)。這是(shi)目前首個(ge)也(ye)(ye)是(shi)唯一一個(ge)被批準用(yong)于(yu)(yu)治(zhi)療從嬰(ying)兒(er)期到(dao)成年期覆蓋全年齡(ling)人(ren)群(qun)的(de)中(zhong)重(zhong)(zhong)度(du)特應性皮(pi)炎靶向生物制(zhi)劑(ji)，也(ye)(ye)是(shi)同(tong)類(lei)首個(ge)可(ke)(ke)用(yong)于(yu)(yu)6個(ge)月及以上(shang)嬰(ying)幼兒(er)的(de)治(zhi)療用(yong)生物制(zhi)劑(ji)。(醫藥健聞)
